BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37921944)

  • 1. Advances in Treatment of Diffuse Midline Gliomas.
    Cacciotti C; Wright KD
    Curr Neurol Neurosci Rep; 2023 Dec; 23(12):849-856. PubMed ID: 37921944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
    Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
    Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
    Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
    Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midline Gliomas: A Retrospective Study from a Cancer Center in the Middle East.
    Al Sharie S; Abu Laban D; Nazzal J; Iqneibi S; Ghnaimat S; Al-Ani A; Al-Hussaini M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy approaches for the treatment of diffuse midline gliomas.
    Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
    Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
    Wang YZ; Zhang YW; Liu WH; Chai RC; Cao R; Wang B; An SY; Jiang WJ; Xu YL; Yang J; Jia WQ
    Neurosurgery; 2021 Jul; 89(2):300-307. PubMed ID: 34015818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.
    Dahl NA; Danis E; Balakrishnan I; Wang D; Pierce A; Walker FM; Gilani A; Serkova NJ; Madhavan K; Fosmire S; Green AL; Foreman NK; Venkataraman S; Vibhakar R
    Cell Rep; 2020 Apr; 31(1):107485. PubMed ID: 32268092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
    Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
    Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T cell therapies for diffuse midline glioma.
    Thomas BC; Staudt DE; Douglas AM; Monje M; Vitanza NA; Dun MD
    Trends Cancer; 2023 Oct; 9(10):791-804. PubMed ID: 37541803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.
    Argersinger DP; Rivas SR; Shah AH; Jackson S; Heiss JD
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
    Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
    Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.